18 unknown, 11 recruiting, 4 not yet recruiting, 3 completed. 41 Phase 2, 2 Phase 3, 1 Phase 1.
Follow HAIC: new trials by email Literature Review of HAIC trials Research Report on HAIC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine | Phase 2 | Not yet recruiting | Xiang-Qian | 120 | 2027-09-01 | 2026-08-27 |
| HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC hepatic arterial infusion chemotherapy (HAIC) combine with QL1706 and bevacizumab - Intrahepatic Cholangiocarcinoma | Phase 2 | Recruiting | Lianghe Lu | 35 | 2026-06-11 | 2026-09-25 |
| The DoHAICs Study Expansion Phase Donafenib, sintilimab, HAIC - HCC - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 90 | 2026-05-20 | 2026-05-13 |
| Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma FOLFOX regimen, Immunotherapy, targeted therapy - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | BinYong Liang | 100 | 2026-04-30 | 2026-04-13 |
| Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma Bevacizumab Biosimilar IBI305, ipilimumab N01, Sintilimab - HCC - Hepatocellular Carcinoma, Conversion Therapy | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 43 | 2026-03-30 | 2026-05-01 |
| Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes Epalrestat, Donafenib + Tislelizumab, HAIC - HCC - Hepatocellular Carcinoma, Diabetes | Phase 2 | Recruiting | Haibo Shao | 32 | 2026-01-21 | 2026-11-10 |
| Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer HAIC, Gemcitabine plus Cisplatin, Adebrelimab - Biliary Tract Cancer | Phase 2 | Recruiting | Air Force Military Medical University, China | 124 | 2025-12-10 | 2026-05-06 |
| HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) Camrelizumab, Rivoceranib (Apatinib), HAIC - Mixed Hepatocellular-cholangiocarcinoma | Phase 2 | Recruiting | Fudan University | 45 | 2025-08-15 | 2025-08-17 |
| HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03) Sintilimab, Bevacizumab Biosimilar, HAIC - Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | Fudan University | 164 | 2025-03-18 | 2026-04-21 |
| ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC Lenvatinib, Pembrolizumab, Atezolizumab - HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Peking Union Medical College Hospital | 300 | 2025-02-19 | 2025-12-01 |
| HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC PD-L1 inhibitor, HAIC - ICC, Advanced Cancer | Phase 2 | Recruiting | Eastern Hepatobiliary Surgery Hospital | 50 | 2025-01-01 | 2026-01-23 |
| Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma Donafenib, Sintilimab, HAIC - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2024-07-30 | 2024-07-22 |
| Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma HAIC, Lenvatinib plus pucotenlimab - Cholangiocarcinoma Non-resectable | Phase 2 | Recruiting | Tongji Hospital | 36 | 2024-06-04 | 2026-07-22 |
| A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC Adebrelimab - Intrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2024-05-10 | 2024-04-19 |
| Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma Adebrelimab - Adebrelimab, Hepatocellular Carcinoma | Phase 2 | Suspended | Tianjin Medical University Cancer Institute and Hospital | 40 | 2024-05-01 | 2026-05-29 |
| First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC Radiotherapy, HAIC (GEMOX), Chemotherapy - Intrahepatic Cholangiocarcinoma | Phase 2 | Terminated | Shandong Cancer Hospital and Institute | 1 | 2024-04-01 | 2025-06-25 |
| Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）. Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） - Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2024-03-14 | 2024-04-19 |
| Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC HAIC, Adebrelimab, Apatinib - Intrahepatic Cholangiocarcinoma | Phase 2 | Recruiting | Lei ZHAO | 20 | 2024-03-01 | 2024-04-17 |
| Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer HAIC, Surufatinib, Tislelizumab - Carcinoma, Intrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 41 | 2023-11-01 | 2023-11-18 |
| Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC HAIC, Sintilimab, Lenvatinib - HCC | Phase 2 | Recruiting | Lei ZHAO | 40 | 2023-10-25 | 2025-04-01 |
Showing 20 of 41. Sign in to see all of them.
Carcinoma, Hepatocellular (23) · Cholangiocarcinoma (6) · Colorectal Neoplasms (3) · Carcinoma (2) · Liver Neoplasms (2) · Biliary Tract Neoplasms (1) · Diabetes Mellitus (1) · Digestive System Neoplasms (1) · Gallbladder Neoplasms (1)
Tianjin Medical University Cancer Institute and Hospital (9) · Fudan University (3) · Peking University (3) · Peking University Cancer Hospital & Institute (3) · Lei ZHAO (2) · Sun Yat-sen University (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · Air Force Military Medical University, China (1) · BinYong Liang (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Eastern Hepatobiliary Surgery Hospital (1) · Haibo Shao (1) · Hui-Chuan Sun (1) · HuiKai Li (1) · Lianghe Lu (1)
China (35)
Xiaodong Wang, MD (2) · Baocai Xing, Doctor (1) · Haibo Shao (1) · Hui-Chuan Sun, MD&PhD (1) · Jin Bo Yue, Dr. (1) · Lei Zhang, PHD (1) · Li Bing, PhD. (1) · Min-shan Chen, MD, PhD (1) · Ming Shi, MD (1) · Tao Han (1) · Wanguang Zhang, M.D.,Ph.D. Wanguang Zhang, M.D.,Ph.D., M.D.,Ph.D. (1) · Xu Zhu, Doctor (1) · Xu Zhu, MD (1) · Ze-yang Ding (1)
PMID 40812353, PMID 19491285, PMID 20375404, PMID 25111859, PMID 25995680, PMID 26695839, PMID 27095655, PMID 28596308, PMID 30785198, PMID 32372672, PMID 35103539, PMID 40475000, PMID 41537370